Late Stage CKD Therapeutics Market to Reach $25.2 Billion by 2032

Industry
โดย ResearchAndMarkets.com·Read original
Summary · why it matters

The global late stage chronic kidney disease therapeutics market, valued at $13.02 billion in 2025, is projected to grow at a compound annual growth rate of 9.88% to reach $25.20 billion by 2032, according to a new report from ResearchAndMarkets.com. The market is being reshaped by integrated cardio-renal-metabolic strategies, a shift toward real-world evidence, and the influence of site-of-care economics on formulary adoption. Key players profiled in the competitive landscape include AbbVie Inc., Akebia Therapeutics, Inc., Amgen Inc., Ardelyx, Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim International GmbH, Chinook Therapeutics, Inc., Eli Lilly and Company, FibroGen, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, KBP Biosciences Co., Ltd., Maze Therapeutics, Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., ProKidney, Inc., and Travere Therapeutics, Inc. The report highlights opportunities in aligning therapies with operational workflows and leveraging real-world evidence for competitive advantage.

Impact on stocks 15

Biotech & Genomic Medicine▲ · 13 stocks
Aging Population▲ · 1 stocks
Health Care▲ · 1 stocks

Off-coverage companies 2

Boehringer Ingelheim International GmbHPrivate± Mixed
relevance

KBP BiosciencesPrivate± Mixed
relevance

© 2026 MarketDXNews